NCT05549583View on ClinicalTrials.gov

Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

April 25, 2018

Study Completion Date

April 25, 2018

Conditions
BioequivalenceType 2 Diabetes
Interventions
DRUG

Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet

The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet

Trial Locations (1)

H3P 3P1

Algorithme Pharma, Mount Royal

Sponsors

Lead Sponsor

Galenicum Health
All Listed Sponsors
lead

Galenicum Health

INDUSTRY

NCT05549583 - Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter